KDM1A在肿瘤耐药中的分子机制研究.PDFVIP

KDM1A在肿瘤耐药中的分子机制研究 本课堂有麦递途工贸（上海）有限公司赞助 耐药机制 RBW7与LSD1 肺癌，DNA损伤 去泛素化修饰 逐步加药法，筛选耐药细胞，检测发现耐药细胞系中KDM1A高表达，干扰掉KDM1A后，索拉菲 尼耐药细胞比例下降 Sorafenib-resistant hepatoma cells acquire stem-like properties 逐步加药法，筛选出耐药细胞系，在耐药细胞中可以看到干细胞表面标志物， Lrg5,sox9,nanog,CD90表达量升高，耐药细胞的克隆形成能力增强。 耐药细胞中，干基因标志物lgr5表达量 升高 Resistant cells were relatively insensitive to sorafenib and exhibited enhanced stem-like properties compared to parental cells, suggesting that stem-like properties are acquired during the development of sorafenib resistance in hepatocellular carcinoma Histone